Novartis acquired Hexal AG and Eon Labs for EUR 5.65 billion ($8.29 billion) in an all-cash transaction, creating the world's largest generics pharmaceutical company through its Sandoz division. Hexal was Germany's No. 2 generics company with EUR 1.65 billion in 2004 sales.
Key facts
AnnouncedDec 18, 2002
ClosedJun 06, 2005
Deal value$8.3B
Deal typeAcquisition/Merger
Therapeutic areaNeurology
Key assetsHexal AG German generics portfolio, Eon Labs US generics portfolio, Combined European and US generics manufacturing, Generic portfolio